HOME¥NEWS&EVENTS SYMPOSIA RESEARCH / GRANT OTHER ACTIVITIES CONTACT HIRF
 
About HIRF
  1. Mission
  2. Management
  3. History
  4. Affiliates

About ICVS

  • 2001 Tokyo
  • 2003 Beijing
  • 2004 London
  • 2006 Washington DC
  • 2007 Vienna
  • 2008 New York
Research
Grant Programs
  • Clinical Trials
  • Education
  • Training
  • Publication

Recommended Links

Contact HIRF

Profile:

Professor Cornelis J.M. MELIEF (2004, 2006)

Prof dr Cornelis J.M. Melief, M.D., Ph.D, is a professor of internal medicine specialized in gimmunohematologyh at Leiden University and head of the LUMCfs Department of Immunohematology and Blood Transfusion, where he leads an internationally acclaimed group focusing on the elucidation of immunological mechanisms that can lead to effective clinically applicable T cell-based immunotherapy of cancer. He received his Ph.D. degree in 1967 from the University of Amsterdam, where he also received his M.D. degree in 1970. He spent two years (1973/1974) as a postdoctoral fellow at the New England Medical Center and Dana Farber Cancer Center (Harvard) in Boston. Of his many contributions to basic immunology, including work in mouse models, and clinical immunology, the most striking highlights are the eradication of large established mouse tumors by adoptive transfer of cytotoxic T lymphocyte clones against defined MHC class I presented peptides, and the discovery that T cell help for cytotoxic T lymphocyte induction involves cognate interaction between CD40 ligand on T helper cells and CD40 on Dendritic Cells. This is a major novel pathway of cytotoxic T lymphocyte induction in non-inflammatory conditions.